Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Dermatitis-Pipeline Review, H1 2015

Dermatitis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Dermatitis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Dermatitis-Pipeline Review, H1 2015', provides an overview of the Dermatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Dermatitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dermatitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dermatitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dermatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 6

Dermatitis Overview 7

Therapeutics Development 8

Dermatitis-Therapeutics under Development by Companies 10

Dermatitis-Therapeutics under Investigation by Universities/Institutes 18

Dermatitis-Pipeline Products Glance 19

Dermatitis-Products under Development by Companies 23

Dermatitis-Products under Investigation by Universities/Institutes 32

Dermatitis-Companies Involved in Therapeutics Development 33

Dermatitis-Therapeutics Assessment 120

Drug Profiles 132

Dermatitis-Recent Pipeline Updates 296

Dermatitis-Dormant Projects 344

Dermatitis-Discontinued Products 357

Dermatitis-Product Development Milestones 359

Appendix 365

List of Tables

Number of Products under Development for Dermatitis, H1 2015 23

Number of Products under Development for Dermatitis-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 26

Number of Products under Development by Companies, H1 2015 (Contd..1) 27

Number of Products under Development by Companies, H1 2015 (Contd..2) 28

Number of Products under Development by Companies, H1 2015 (Contd..3) 29

Number of Products under Development by Companies, H1 2015 (Contd..4) 30

Number of Products under Development by Companies, H1 2015 (Contd..5) 31

Number of Products under Development by Companies, H1 2015 (Contd..6) 32

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Late Stage Development, H1 2015 34

Comparative Analysis by Clinical Stage Development, H1 2015 35

Comparative Analysis by Early Stage Development, H1 2015 36

Comparative Analysis by Unknown Stage Development, H1 2015 37

Products under Development by Companies, H1 2015 38

Products under Development by Companies, H1 2015 (Contd..1) 39

Products under Development by Companies, H1 2015 (Contd..2) 40

Products under Development by Companies, H1 2015 (Contd..3) 41

Products under Development by Companies, H1 2015 (Contd..4) 42

Products under Development by Companies, H1 2015 (Contd..5) 43

Products under Development by Companies, H1 2015 (Contd..6) 44

Products under Development by Companies, H1 2015 (Contd..7) 45

Products under Development by Companies, H1 2015 (Contd..8) 46

Products under Investigation by Universities/Institutes, H1 2015 47

Dermatitis-Pipeline by AlbireoPharma, H1 2015 48

Dermatitis-Pipeline by Amorepacific Corporation, H1 2015 49

Dermatitis-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 50

Dermatitis-Pipeline by AnaMar AB, H1 2015 51

Dermatitis-Pipeline by AnaptysBio, Inc., H1 2015 52

Dermatitis-Pipeline by AnGes MG, Inc., H1 2015 53

Dermatitis-Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 54

Dermatitis-Pipeline by arGEN-X BV, H1 2015 55

Dermatitis-Pipeline by Biomar Microbial Technologies, H1 2015 56

Dermatitis-Pipeline by Blueberry Therapeutics Ltd, H1 2015 57

Dermatitis-Pipeline by Brickell Biotech, Inc., H1 2015 58

Dermatitis-Pipeline by Bristol-Myers Squibb Company, H1 2015 59

Dermatitis-Pipeline by Celgene Corporation, H1 2015 60

Dermatitis-Pipeline by Celsus Therapeutics Plc, H1 2015 61

Dermatitis-Pipeline by ChemoCentryx, Inc., H1 2015 62

Dermatitis-Pipeline by China Biologic Products, Inc., H1 2015 63

Dermatitis-Pipeline by ChironWells GmbH, H1 2015 64

Dermatitis-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 65

Dermatitis-Pipeline by Circassia Pharmaceuticals plc, H1 2015 66

Dermatitis-Pipeline by Convoy Therapeutics, Inc., H1 2015 67

Dermatitis-Pipeline by Creabilis SA, H1 2015 68

Dermatitis-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 69

Dermatitis-Pipeline by Dermira Inc., H1 2015 70

Dermatitis-Pipeline by Eisai Co., Ltd., H1 2015 71

Dermatitis-Pipeline by EpiPharm AG, H1 2015 72

Dermatitis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 73

Dermatitis-Pipeline by FAES Farma SA, H1 2015 74

Dermatitis-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 75

Dermatitis-Pipeline by Fountain Biopharma Inc., H1 2015 76

Dermatitis-Pipeline by GlaxoSmithKline plc, H1 2015 77

Dermatitis-Pipeline by GlycaNova Norway AS, H1 2015 78

Dermatitis-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 79

Dermatitis-Pipeline by Han Wha Pharma Co., Ltd., H1 2015 80

Dermatitis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 81

Dermatitis-Pipeline by Herantis Pharma plc., H1 2015 82

Dermatitis-Pipeline by IMMD Inc., H1 2015 83

Dermatitis-Pipeline by Immune Response BioPharma, Inc., H1 2015 84

Dermatitis-Pipeline by Inflamalps SA, H1 2015 85

Dermatitis-Pipeline by Janssen Research & Development, LLC, H1 2015 86

Dermatitis-Pipeline by Johnson & Johnson, H1 2015 87

Dermatitis-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 88

Dermatitis-Pipeline by LegoChem Biosciences, Inc, H1 2015 89

Dermatitis-Pipeline by LEO Pharma A/S, H1 2015 90

Dermatitis-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 91

Dermatitis-Pipeline by Madam Therapeutics B.V., H1 2015 92

Dermatitis-Pipeline by Marinomed Biotechnologie GmbH, H1 2015 93

Dermatitis-Pipeline by Maruho Co., Ltd., H1 2015 94

Dermatitis-Pipeline by MedImmune, LLC, H1 2015 95

Dermatitis-Pipeline by Merck & Co., Inc., H1 2015 96

Dermatitis-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 97

Dermatitis-Pipeline by Nabriva Therapeutics AG, H1 2015 98

Dermatitis-Pipeline by NeoPharm Co., Ltd., H1 2015 99

Dermatitis-Pipeline by Novan, Inc., H1 2015 100

Dermatitis-Pipeline by Novartis AG, H1 2015 101

Dermatitis-Pipeline by Nuvo Research Inc., H1 2015 102

Dermatitis-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 103

Dermatitis-Pipeline by Oxagen Limited, H1 2015 104

Dermatitis-Pipeline by Pergamum AB, H1 2015 105

Dermatitis-Pipeline by Pfizer Inc., H1 2015 106

Dermatitis-Pipeline by Pharis Biotec GmbH, H1 2015 107

Dermatitis-Pipeline by Pharmedartis GmbH, H1 2015 108

Dermatitis-Pipeline by Phosphagenics Limited, H1 2015 109

Dermatitis-Pipeline by ProCertus BioPharm Inc., H1 2015 110

Dermatitis-Pipeline by Promius Pharma, LLC, H1 2015 111

Dermatitis-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 112

Dermatitis-Pipeline by R-Tech Ueno, Ltd., H1 2015 113

Dermatitis-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 114

Dermatitis-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 115

Dermatitis-Pipeline by RestorGenex Corporation, H1 2015 116

Dermatitis-Pipeline by Stemnion, Inc, H1 2015 117

Dermatitis-Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 118

Dermatitis-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 119

Dermatitis-Pipeline by SWITCH Biotech LLC, H1 2015 120

Dermatitis-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 121

Dermatitis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 122

Dermatitis-Pipeline by Thesan Pharmaceuticals, Inc., H1 2015 123

Dermatitis-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 124

Dermatitis-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 125

Dermatitis-Pipeline by Vicore Pharma AB, H1 2015 126

Dermatitis-Pipeline by Vida Therapeutics Inc., H1 2015 127

Dermatitis-Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 128

Dermatitis-Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 129

Dermatitis-Pipeline by Welichem Biotech Inc., H1 2015 130

Dermatitis-Pipeline by XBiotech USA, Inc., H1 2015 131

Dermatitis-Pipeline by Xencor, Inc., H1 2015 132

Dermatitis-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 133

Dermatitis-Pipeline by Ziarco Pharma Ltd, H1 2015 134

Assessment by Monotherapy Products, H1 2015 135

Number of Products by Stage and Target, H1 2015 137

Number of Products by Stage and Mechanism of Action, H1 2015 141

Number of Products by Stage and Route of Administration, H1 2015 144

Number of Products by Stage and Molecule Type, H1 2015 146

Dermatitis Therapeutics-Recent Pipeline Updates, H1 2015 311

Dermatitis-Dormant Projects, H1 2015 359

Dermatitis-Dormant Projects (Contd..1), H1 2015 360

Dermatitis-Dormant Projects (Contd..2), H1 2015 361

Dermatitis-Dormant Projects (Contd..3), H1 2015 362

Dermatitis-Dormant Projects (Contd..4), H1 2015 363

Dermatitis-Dormant Projects (Contd..5), H1 2015 364

Dermatitis-Dormant Projects (Contd..6), H1 2015 365

Dermatitis-Dormant Projects (Contd..7), H1 2015 366

Dermatitis-Dormant Projects (Contd..8), H1 2015 367

Dermatitis-Dormant Projects (Contd..9), H1 2015 368

Dermatitis-Dormant Projects (Contd..10), H1 2015 369

Dermatitis-Dormant Projects (Contd..11), H1 2015 370

Dermatitis-Dormant Projects (Contd..12), H1 2015 371

Dermatitis-Discontinued Products, H1 2015 372

Dermatitis-Discontinued Products (Contd..1), H1 2015 373

List of Figures

Number of Products under Development for Dermatitis, H1 2015 23

Number of Products under Development for Dermatitis-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Late Stage Development, H1 2015 34

Comparative Analysis by Clinical Stage Development, H1 2015 35

Comparative Analysis by Early Stage Products, H1 2015 36

Assessment by Monotherapy Products, H1 2015 135

Number of Products by Top 10 Targets, H1 2015 136

Number of Products by Stage and Top 10 Targets, H1 2015 136

Number of Products by Top 10 Mechanism of Actions, H1 2015 140

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 140

Number of Products by Top 10 Routes of Administration, H1 2015 143

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 144

Number of Products by Top 10 Molecule Types, H1 2015 145

Number of Products by Stage and Top 10 Molecule Types, H1 2015 145

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AlbireoPharma

Amorepacific Corporation

Anacor Pharmaceuticals, Inc.

AnaMar AB

AnaptysBio, Inc.

AnGes MG, Inc.

Aquinox Pharmaceuticals Inc.

arGEN-X BV

Biomar Microbial Technologies

Blueberry Therapeutics Ltd

Brickell Biotech, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Celsus Therapeutics Plc

ChemoCentryx, Inc.

China Biologic Products, Inc.

ChironWells GmbH

Chugai Pharmaceutical Co., Ltd.

Circassia Pharmaceuticals plc

Convoy Therapeutics, Inc.

Creabilis SA

Daiichi Sankyo Company, Limited

Dermira Inc.

Eisai Co., Ltd.

EpiPharm AG

F. Hoffmann-La Roche Ltd.

FAES Farma SA

Foamix Pharmaceuticals Ltd.

Fountain Biopharma Inc.

GlaxoSmithKline plc

GlycaNova Norway AS

Grupo Ferrer Internacional, S.A.

Han Wha Pharma Co., Ltd.

HanAll Biopharma Co., Ltd.

Herantis Pharma plc.

IMMD Inc.

Immune Response BioPharma, Inc.

Inflamalps SA

Janssen Research & Development, LLC

Johnson & Johnson

Kyowa Hakko Kirin Co., Ltd.

LegoChem Biosciences, Inc

LEO Pharma A/S

Lixte Biotechnology Holdings, Inc.

Madam Therapeutics B.V.

Marinomed Biotechnologie GmbH

Maruho Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Mitsubishi Tanabe Pharma Corporation

Nabriva Therapeutics AG

NeoPharm Co., Ltd.

Novan, Inc.

Novartis AG

Nuvo Research Inc.

Otsuka Holdings Co., Ltd.

Oxagen Limited

Pergamum AB

Pfizer Inc.

Pharis Biotec GmbH

Pharmedartis GmbH

Phosphagenics Limited

ProCertus BioPharm Inc.

Promius Pharma, LLC

Provectus Biopharmaceuticals, Inc.

R-Tech Ueno, Ltd.

Reata Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

RestorGenex Corporation

Stemnion, Inc

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd.

SWITCH Biotech LLC

Taisho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Thesan Pharmaceuticals, Inc.

Upsher-Smith Laboratories, Inc.

Valeant Pharmaceuticals International, Inc.

Vicore Pharma AB

Vida Therapeutics Inc.

Vitae Pharmaceuticals, Inc.

VivaCell Biotechnology Espana S.L.

Welichem Biotech Inc.

XBiotech USA, Inc.

Xencor, Inc.

Yungjin Pharm Ind. Co., Ltd.

Ziarco Pharma Ltd

Dermatitis Therapeutic Products under Development, Key Players in Dermatitis Therapeutics, Dermatitis Pipeline Overview, Dermatitis Pipeline, Dermatitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com